Nimotuzumab with Concurrent Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN)

Journals Menu

Follow SCIRP

	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org

Citations

Journals Menu

"Nimotuzumab with Concurrent Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN)"
written by Naresh Somani,
published by Journal of Cancer Therapy, Vol.6 No.4, 2015

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer-A case report from a tertiary cancer center
	2021

[2]	Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck …
	2019

[3]	Retracted: Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway
	2019

[4]	Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural …
	2019

[5]	Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An …
	2019

[6]	Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway
	2019

[7]	Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and …
	2019

[8]	Joint Editors: Dr. Kumar Prabhash
	2019

[9]	Nimotuzumab with concurrent chemoradiation in inoperable locally advanced squamous cell carcinoma of head and neck: An Indian experience
	2018

[10]	Monoclonal antibody‐based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
	Journal of Pharmacy and Pharmacology, 2018

[11]	Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based …
	2018

[12]	Clinical immunotherapeutic approaches for the treatment of head and neck cancer
	International Journal of Oral and Maxillofacial Surgery, 2018

[13]	Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
	2018

[14]	Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: a hospital-based retrospective …
	2018

[15]	Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer
	2017

[16]	Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of …
	2017

[17]	Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and …
	2017

[1]	Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER Journal of Pharmacy and Pharmacology, 2018 DOI:10.1111/jphp.12911

[2]	Clinical immunotherapeutic approaches for the treatment of head and neck cancer International Journal of Oral and Maxillofacial Surgery, 2018 DOI:10.1016/j.ijom.2018.10.012

[3]	Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER Journal of Pharmacy and Pharmacology, 2018 DOI:10.1111/jphp.12911

Follow SCIRP

	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

Journal of Cancer Therapy

Journals Menu

Home

About SCIRP

Service

Policies